Sugammadex and Smoker's Neuromuscular Block

The Evaluation of the Effects of the Use of Rocuronium and Sugammadex on Neuromuscular Block in Smoker

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05313100

Enrollment

Registered

2022-04-06

Start date

2012-04-30

Completion date

2013-08-31

Last updated

2022-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Blockade, Smoking

Keywords

sugammadex, smoking, neuromuscular blockade

Brief summary

We compared the durations of antagonizing and of the severity of effect of sugammadex used in antagonizing the rocuronium in smoker and non-smoker total 40 patients with using Train of Four(TOF) neuromuscular monitorization.

Detailed description

40 patients from American Society of Anesthesiologist (ASA) I- II class, being smokers for at least 10 years or non-smokers, who will undergo elective surgery were included in this randomized prospective study. Patients underwent routine monitoring and neuromuscular monitoring. Propofol 2 mg/kg and intravenous fentanyl 1 mcg/kg were applied at induction. After the loss of eyelash reflex, intravenous rocuronium 0,6 mg/kg was administered. The patient was intubated at a Train of Four count of 2. Anesthesia was continued with 50% O2 + 50% air and sevoflurane 2 % . Rocuronium 0,15 mg/kg was administered when TOF (Train of Four) counter reached 2 during the operation. Sugammadex 2 mg/kg was administered at the end of the operation. The time to reach Train of Four values of 0,7-0,8-0,9 were recorded.

Interventions

DRUGsugammadex

At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Elective surgery, * 1-2 according to the ASA ( American Society of Anesthesiologist ) physical status classification. * Patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking * Or never smoked patients

Exclusion criteria

* neuromuscular diseases * radiotherapy and/or chemotherapy anamnesis, * liver and/or renal disease, * electrolyte balance, * history of drug use which affects neuromuscular transmission, * Body Mass Index (BMI) of more than 27, * use alcohol

Design outcomes

Primary

Measure	Time frame	Description
Neuromuscular block recovery time	six months	Time to reach TOF %90 measurement after given neuromuscular blocker reverse agent

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026